AUTHORS
Xiaoyan Qu, Haisheng Liu2, Yajing Zhang3, Kaiyang Ding, MD4, Heng Mei5, Jujuan Wang6, Sanmei Wang, MD, PhD7, Haorui Shen, MD8, Zhengxu Sun9, Shuangshuang Xing10, Zheng Li11, Cuiying He, MD12, Guoai Su, MD, MS13, Lin Liu14, Ran Li15, Hailing Liu16, Ling Zhou17, Yinrui Jiang, MD18, Yongxin Luo19, Baoming Nie20, Dong Geng21, Guowei Fang22, Cong Feng23, Cheng Wang24, Da Xu25, Fei Wang26, Ying He27, Bing Gao28, Jing Wang29, Xiaoyu Feng30, Lei Fan, MD31
AFFILIATIONS
1 The First Affiliated Hospital with Nanjing Medical University, Jiangsu Province Hospital, Nanjing, China
2 The Fourth Hospital of Hebei Medical University, Shijiazhuang, China
3 Beijing GoBroad Boren Hospital, Gobroad Medical Institute of Hematology, Beijing, China
4 The First Affiliated Hospital of USTC West District, Hefei, China
5 Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China
6 The First Affiliated Hospital with Nanjing Medical University, Jiangsu Province Hospital, Nanjing, China
7 The First Affiliated Hospital with Nanjing Medical University, Jiangsu Province Hospital, Nanjing, China
8 The First Affiliated Hospital with Nanjing Medical University, Jiangsu Province Hospital, Nanjing, China
9 The First Affiliated Hospital with Nanjing Medical University, Jiangsu Province Hospital, Nanjing, China
10 The First Affiliated Hospital with Nanjing Medical University, Jiangsu Province Hospital, Nanjing, China
11 The Fourth Hospital of Hebei Medical University, Shijiazhuang, China
12 The Fourth Hospital of Hebei Medical University, Shijiazhuang, China
13 Beijing GoBroad Boren Hospital, Gobroad Medical Institute of Hematology, Beijing, China
14 Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China
15 The First Affiliated Hospital with Nanjing Medical University, Jiangsu Province Hospital, Nanjing, China
16 The First Affiliated Hospital with Nanjing Medical University, Jiangsu Province Hospital, Nanjing, China
17 Nanjing Legend Biotech Co Ltd, Nanjing, China
18 Nanjing Legend Biotech Co Ltd, Nanjing, China
19 Nanjing Legend Biotech Co Ltd, Nanjing, China
20 Legend Biotech USA Inc, Bridgewater, New Jersey, United States
21 Legend Biotech USA Inc, Bridgewater, New Jersey, United States
22 Legend Biotech USA Inc, Bridgewater, New Jersey, United States
23 Nanjing Legend Biotech Co Ltd, Nanjing, China
24 Nanjing Legend Biotech Co Ltd, Nanjing, China
25 Nanjing Legend Biotech Co Ltd, Nanjing, China
26 Nanjing Legend Biotech Co Ltd, Nanjing, China
27 Nanjing Legend Biotech Co Ltd, Nanjing, China
28 Nanjing Legend Biotech Co Ltd, Nanjing, China
29 Nanjing Legend Biotech Co Ltd, Nanjing, China
30 Nanjing Legend Biotech Co Ltd, Nanjing, China
31 The First Affiliated Hospital with Nanjing Medical University, Jiangsu Province Hospital, Nanjing, China
ABSTRACT
Introduction:
Ex vivo CAR-T therapies have advanced treatment for relapsed/refractory B-cell non-Hodgkin lymphoma (R/R B-NHL); however, their widespread use is limited by complex manufacturing and lymphodepletion. LB2501 is a third-generation, self-inactivating lentiviral vector designed to transduce endogenous T cells and generate CAR-T cells directly within the patient, eliminating the need for leukapheresis, ex vivo manufacturing, or lymphodepletion. We reported preliminary results from the first 12 patients in the FIH study of LB2501 in R/R NHL (EHA 2026, LB5006). Herein, we present an update with 19 patients and extended follow up.
Methods:
This phase 1 trial (NCT07002112) is an open-label, multicenter, dose-escalation study being conducted at 5 sites. Eligible patients had histologically confirmed B-NHL and relapsed disease after 2 or more prior lines of therapy (LOT) or refractory after at least 1 LOT. Enrolled patients received a single intravenous infusion of LB2501 without lymphodepletion. A standard 3 + 3 design with backfilling was applied for prespecified dose levels. The primary endpoints were safety, tolerability, and pharmacokinetics.
Results:
As of Jun 28th, 2026, 19 patients had received an infusion of LB2501 at DL1 (n=6), DL2 (n=8), or DL3 (n=5). Median age was 59.0 years, 4 (21.1%) ≥ 65 years and 8 (42.1%) male. The patients included 12 (63.2%) LBCL, 5 (26.4%) iNHL [4 (21.1%) FL and 1(5.3%) MZL], and 2 (10.5%) MCL. Thirteen (68.4%) patients had Ann Arbor stage III or IV disease. Median lines of prior therapy were 2; 3 (15.8%) were primary refractory disease, and 12 (63.2%) were refractory to the last LOT. Prior treatment with CD19 autologous CAR-T cells and CD3×CD20 T-cell engagers were in 5.3% and 15.8% of patients, respectively.
Median screening to infusion time was 17.0 days without bridging therapy. With a median follow up of 4.80 mo (range: 1.0–10.3 mo) for all patients, no DLT or deaths occurred. One SAE (5.3%, Grade 2 IEC-HS) was reported at DL3, related to in vivo-generated CAR-T cells. Grade ≥ 3 TEAEs related to LVV and in vivo-generated CAR-T cells were 42.1% and 63.2% respectively; the most common grade 3 or 4 TEAEs were hematologic events. IRRs occurred in 16 (84.2%) patients, all grades 1 or 2 and resolved with a median duration of 20.6 hrs. No prophylactic or therapeutic use of tocilizumab or glucocorticoids was required for IRRs. CRS occurred in 15 (78.9%) patients (Grade 1 in 63.2%, Grade 2 in 15.8%). The median time to CRS onset was 10 days, with a median duration of 5.0 days. No ICANS, non-ICANS, or other neurotoxicities were reported.
By the cut-off date, the overall ORR and CR rate were 57.9% (11/19). No responses were observed at DL1, both the ORR and CR rate were 100% (8/8) at DL2, and both the ORR and CR rate were 60% (3/5) at DL3. Deepening of the response was observed over time, with the longest duration of response being up to 5 months. Median PFS has not been reached.
PK analysis via qPCR confirmed in vivo CAR-T cell expansion in 83% (5/6) of patients at DL1, 100% (8/8) at DL2, and 100% (5/5) at DL3. Median Cmax values were 1068.0, 96,564.5, and 23,802.0 copies/μg gDNA, with corresponding median Tmax values of 17.0, 15.0, and 13.0 days at DL1, DL2, and DL3. Phenotype analysis of the CAR-T cells at peak showed that they were predominantly CD8+. At the time of data cutoff, 1 patient maintained detectable CAR-T cells in peripheral blood for up to 179 days, with a high percentage of central memory phenotype.
In vivo transduction is highly T-cell specific, and the VCN is approximately 1 (mostly single copy per T cell), which is lower than that of ex vivo-manufactured CAR-T cell products.
Conclusions:
LB2501, a first-in-class CD19/CD20 dual-targeting in vivo vector, introduces a novel paradigm of CAR-T therapy, eliminating the need for ex vivo manufacturing and lymphodepletion. LB2501 has demonstrated a favorable safety profile and encouraging efficacy with 100% ORR and CR rate at DL2 with duration up to 5 months. Although longer follow up is warranted, these data underscore the potential of LB2501 as a scalable, readily accessible off-the-shelf, out-patient use immunotherapy for B-cell malignancies.
DISCLOSURES
Lei Fan, MD: No relevant conflicts of interest to declare.